Editorial & Opinion
Prior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab.
| العنوان: | Prior exposure to fumaric acid esters does not impact on subsequent treatment response to guselkumab. |
|---|---|
| المؤلفون: | Kearney N; Department of Dermatology, Ulster Hospital Dundonald, South Eastern Health and Social Care Trust, UK., Kirby B; Department of Dermatology, St. Vincent's University Hospital Dublin, Ireland.; Charles Institute of Dermatology, University College Dublin, Ireland. |
| المصدر: | The British journal of dermatology [Br J Dermatol] 2024 Jun 20; Vol. 191 (1), pp. 5-6. |
| نوع المنشور: | Letter; Editorial; Comment |
| اللغة: | English |
| بيانات الدورية: | Publisher: Oxford University Press Country of Publication: England NLM ID: 0004041 Publication Model: Print Cited Medium: Internet ISSN: 1365-2133 (Electronic) Linking ISSN: 00070963 NLM ISO Abbreviation: Br J Dermatol Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2023- : Oxford : Oxford University Press Original Publication: Oxford [etc.] Published for the British Association of Dermatologists by Blackwell Scientific Publications [etc.] |
| مواضيع طبية MeSH: | Fumarates*/therapeutic use , Fumarates*/adverse effects , Antibodies, Monoclonal, Humanized*/therapeutic use , Antibodies, Monoclonal, Humanized*/adverse effects, Humans ; Treatment Outcome ; Male ; Female ; Psoriasis/drug therapy ; Middle Aged ; Adult ; Dermatologic Agents/therapeutic use |
| مستخلص: | Competing Interests: Conflicts of interest N.K. has received honoraria from AbbVie, Janssen, Lilly, Novartis and UCB, and has acted as a subinvestigator in clinical trials for AbbVie, MoonLake and UCB. B.K. has received research support from/was a principal investigator (clinical trials) for AbbVie, Almirall, Janssen, Merck Sharp & Dohme, Novartis, Pfizer and UCB; has been a consultant for AbbVie, Almirall, Celgene, Janssen, Merck Sharp & Dohme, MoonLake, Novartis, Pfizer and UCB; has received honoraria from AbbVie, Almirall, Celgene, Janssen, Lilly, MoonLake, Novartis, Pfizer and UCB; and has been on scientific advisory boards for AbbVie, Almirall, Celgene, Janssen, Lilly, MoonLake, Novartis, Pfizer and UCB. |
| التعليقات: | Comment on: Br J Dermatol. 2024 Jun 20;191(1):36-48. doi: 10.1093/bjd/ljad523. (PMID: 38133615) |
| المشرفين على المادة: | 0 (Fumarates) 0 (Antibodies, Monoclonal, Humanized) 089658A12D (guselkumab) 0 (Dermatologic Agents) |
| تواريخ الأحداث: | Date Created: 20240129 Date Completed: 20240620 Latest Revision: 20240620 |
| رمز التحديث: | 20240621 |
| DOI: | 10.1093/bjd/ljae036 |
| PMID: | 38282352 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1365-2133 |
|---|---|
| DOI: | 10.1093/bjd/ljae036 |